The main demographic and clinical features of patients with axSpA (n = 321) at baseline and treated with TNF-α blockers (ADA = 57, ETN = 87, IFX = 177).
| Characteristics | AS, n = 259 | nr-axSpA, n = 62 |
|---|---|---|
| Male, % | 75 | 50* |
| Age, yrs (median) | 43 (34.0–53.5) | 46.5 (36.3–53.7) |
| Disease duration, mos (median) | 96 (36–189) | 36 (12.5–69)* |
| Articular manifestations, % | ||
| Axial | 100 | 100 |
| Peripheral arthritis | 50.5 | 58 |
| Enthesitis | 35 | 29 |
| Extraarticular manifestations, % | 37.8 | 32.2 |
| Uveitis | 17.3 | 8 |
| Psoriasis | 13.1 | 19.3 |
| IBD | 10.8 | 6 |
| BASDAI (median) | 6 (4.9–7.5) | 5.2 (4.1–6.6) |
| BASFI (median) | 5.8 (4.2–7.5) | 4.3 (2.7–5.3)* |
| BASMI (median) | 3 (2–4.9) | 1 (1–3)* |
| HLA-B27+, % | 64.9 | 58.3 |
| ESR, mm/first h (median) | 30 (17–44) | 21 (13–33)* |
| CRP, mg/dl (median) | 1.4 (0.8–2.6) | 0.6 (0.1–1.2)* |
| Concomitant treatment at baseline, % | ||
| DMARD | 31.6 | 30.9 |
| Prednisone intake | 25.8 | 14.5 |
| NSAID intake | 76.8 | 53.2* |
| Anti-TNF-α therapy, % | ||
| ADA | 18.3 | 16.1 |
| ETN | 28.9 | 16.1 |
| IFX | 52.8 | 67.8** |
↵* p < 0.01.
↵** p < 0.05. axSpA: axial spondyloarthritis; TNF: tumor necrosis factor; ADA: adalimumab; ETN: etanercept; IFX: infliximab; AS: ankylosing spondylitis; nr-axSpA: nonradiographic axSpA; IBD: inflammatory bowel disease; BASDAI: Bath AS Disease Activity Index; BASFI: Bath AS Functional Index; BASMI: Bath AS Metrology Index: ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DMARD: disease-modifying antirheumatic drug; NSAID: nonsteroidal antiinflammatory drug.